Description
DE-OBLIGATION OF EXCESS FUNDS - POPLAR BLUFF VA MEDICAL CENTER
Base award description: VISN 15 CHEMISTRY BPA
Modification chain · 5 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2020-07-01+$7,577,076= $7,577,076
- Mod P000012022-02-08+$19,446= $7,596,522
- Mod P000022022-09-20-$306,150= $7,290,373
- Mod P000062023-07-13-$129,229= $7,161,144
- Mod P000072024-09-24-$75,523= $7,085,621
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2020-07-01 | +$7,577,076 | $7,577,076 | VISN 15 CHEMISTRY BPA |
| Mod P00001· FUNDING ONLY ACTION | 2022-02-08 | +$19,446 | $7,596,522 | VISN 15 CHEMISTRY BPA |
| Mod P00002· FUNDING ONLY ACTION | 2022-09-20 | −$306,150 | $7,290,373 | VISN 15 CHEMISTRY BPA |
| Mod P00006· FUNDING ONLY ACTION | 2023-07-13 | −$129,229 | $7,161,144 | DE-OBLIGATION OF EXCESS FUNDS |
| Mod P00007· OTHER ADMINISTRATIVE ACTION | 2024-09-24 | −$75,523 | $7,085,621 | DE-OBLIGATION OF EXCESS FUNDS - POPLAR BLUFF VA MEDICAL CENTER |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI NH3LDK8CFAK7)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24426N1004 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $187,594 | FY2026 |
| 36C24426N1005 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $395,322 | FY2026 |
| 36C24426N1001 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $431,969 | FY2026 |
| 36C24426N1003 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $267,954 | FY2026 |
| 36C24426N1002 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $607,544 | FY2026 |
| 36C24426N1006 | 244-NETWORK CONTRACT OFFICE 4 (36C244) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $783,641 | FY2026 |
Other recipients under 6640 from 255-NETWORK CONTRACT OFFICE 15 (36C255) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C25526A0038 | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 255-NETWORK CONTRACT OFFICE 15 (36C255) | $0 | FY2026 |
| 36C25526N0419 | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 255-NETWORK CONTRACT OFFICE 15 (36C255) | $206,949 | FY2026 |
| 36C25526N0379 | WERFEN USA LLC | 255-NETWORK CONTRACT OFFICE 15 (36C255) | $671,956 | FY2026 |
| 36C25526P0266 | CELLULAR TECHNOLOGY LIMITED | 255-NETWORK CONTRACT OFFICE 15 (36C255) | $47,525 | FY2026 |
| 36C25526N0349 | QIAGEN, LLC | 255-NETWORK CONTRACT OFFICE 15 (36C255) | $93,253 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C25520N0340_3600_36C25518A0039_3600 · retrieved 2026-09-26.